SHARE BUYBACK TRANSACTIONS
COMPANY ANNOUNCEMENT no. 68 - 16 September 2024 On 9 February 2024, DFDS A/S (“DFDS”) announced the initiation of a share buyback programme to be executed in accordance with EU…
Producers Online
Finding producers online involves identifying the right platforms, networks, and resources where producers showcase their work or are actively seeking projects. Here are some effective strategies:
When reaching out to producers, be clear about your project needs, budget, and timelines. This helps in finding the right match quickly
COMPANY ANNOUNCEMENT no. 68 - 16 September 2024 On 9 February 2024, DFDS A/S (“DFDS”) announced the initiation of a share buyback programme to be executed in accordance with EU…
SELSKABSMEDDELELSE nr. 68 - 16. september 2024 Den 9. februar 2024 meddelte DFDS A/S (“DFDS”) iværksættelsen af et aktietilbage-købsprogram til gennemførsel i henhold til EUs markedsmisbrugsforordning, EU forordning nr. 596/2014…
- Un taux de réponse objective (TRO) cliniquement significatif de 63,3–76,7 % a été observé avec l’association belrestotug + dostarlimab, avec un TRO confirmé (TROc) d'environ 60 % pour chaque…
- Klinisch bedeutsame objektive Ansprechrate (Objective Response Rate, ORR) von 63,3–76,7 % bei der Kombination von Belrestotug + Dostarlimab, mit einer bestätigten ORR (confirmed ORR, cORR) von ca. 60 %…
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12),…
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with increased clinical benefit,…
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset…
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohortResponses with Rina-S were observed…
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did not meet statistical significanceIpsen will…
L’essai portant sur Cabometyx® (cabozantinib) en association avec l’atézolizumab a démontré une tendance positive à l’amélioration de l’un des critères d’évaluation principaux de la survie globale, sans atteindre la significativité…